Aims

The sodium-glucose co-transporter-2 inhibitor empagliflozin reduced the total burden of cardiovascular mortality and all-cause hospitalization events, including first and recurrent events, in EMPA-REG OUTCOME participants with type 2 diabetes (T2D) and established atherosclerotic cardiovascular disease (ASCVD). We investigated the effect of empagliflozin on the total burden of cardiovascular and hospitalization events in Asian participants.

Materials and Methods

Participants were randomized to empagliflozin 10 mg, 25 mg, or placebo plus standard of care. The primary and key secondary outcomes were the composite of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke and the primary outcome plus hospitalization for unstable angina, respectively. The effect of pooled empagliflozin versus placebo on total (first plus recurrent) cardiovascular and hospitalization events was analysed using a negative binomial model that preserves randomization and accounts for within-patient correlation of multiple events. We analysed Asian versus non-Asian EMPA-REG OUTCOME population subgroups post hoc.

Results

Among 1517 Asian participants, empagliflozin reduced relative risk of total events of the primary outcome by 38% versus placebo (rate ratio [95% CI]: 0.62 [0.427, 0.885]), the key secondary outcome by 33% (0.67 [0.479, 0.929]), the composite of cardiovascular death (excluding fatal stroke) and hospitalization for heart failure by 43% (0.57 [0.329, 0.996]), and all-cause hospitalization by 21% (0.79 [0.651, 0.967]). Empagliflozin's effects were consistent between Asian and non-Asian populations (treatment-by-subgroup interaction P-values >0.05).

Conclusions

Empagliflozin reduced the total burden of cardiovascular and hospitalization events in Asian and non-Asian EMPA-REG OUTCOME participants with T2D and established ASCVD, consistent with the overall trial population.

This article is protected by copyright. All rights reserved.